Immunic (IMUX)
(Delayed Data from NSDQ)
$1.25 USD
0.00 (0.00%)
Updated May 28, 2024 04:00 PM ET
After-Market: $1.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 61 - 80 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-935 Shows Favorable Safety, Tolerability & PK Profile in Ph1 SAD/MAD Parts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Impressive MAD Data in Healthys Derisk 2Q2022 Data in Psoriasis Patients
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 1 Data For IMU-935 in Prostate Cancer Expected in 3Q2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-935/mCRPC Phase 1 Initiated; Initial Data Expected in Q3:22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Companies With YE2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Sure-Footed IMUX Gets ENSURE Phase 3''s Underway
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 ENSURE Program of IMU-838 in RRMS Enrolls its First Patient
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Solid Foundation In Place Ahead of Value-Driving Catalysts in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Update - 2022 Teeing Up To Be A Major Value Inflection Point
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
First Psoriasis Patient Dosed with IMU-935 & Data in Healthys by YE2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-935/Psoriasis Ph1 Underway; Initial Results in Q2:22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L